3 Things You (Still) Need to Know About GLP-1 Agonists
July 8, 2015
Incretin mimetic therapy for type 2 diabetes has been on the market for more than 10 years. Find out what you've learned about the GLP-1 agonists, here.
T2 Diabetes
SGLT2 Inhibitor Impact on CV Risk: What We Know Now
May 5, 2015
While we wait for results from FDA-mandated CV outcomes studies by SGLT2I makers, there is plenty of (positive) speculation.
Abridged Diabetes Guidelines for Primary Care: 6 Noteworthy Changes
April 27, 2015
The ADA provides an abridged version for PCPs of its annual Standards of Medical Care. Our slides summarize 6 updates important to primary care.
SGLT2 Inhibitors and Fracture Risk: A Review of What We Know
March 30, 2015
It's probably too early to pass judgment but data from clinical trials point to decreased bone mineral density and increased treatment-emergent fractures in patients taking the new antidiabetes drugs.
Triad of Factors Ups Risk for Type 2 Diabetes
March 27, 2015
New research shows certain women are 43 times more likely to develop type 2 diabetes mellitus after childbirth.
WHO and How Much Sugar?
March 11, 2015
Evidence-based recommendations on the intake of free sugars to reduce the risk of noncommunicable diseases are the ingredients of a new WHO guideline. Find the recipe in these slides.
Risk of Type 2 Diabetes after GDM Can Be Reduced
March 11, 2015
Medical and lifestyle interventions successfully lowered the risk of type 2 diabetes in women with a history of gestational diabetes.
10 New FDA-Approved Endocrinology Drugs
February 27, 2015
Since June of 2014, the US FDA has approved a number of drugs for a variety of endocrine-related diseases. Here are 10 of them.
GLP-1 Receptor Agonists and Cardiovascular Outcomes: 3 Studies
February 20, 2015
Cardiovascular disease is the underlying cause of death in more than 60% of patients with T2DM. GLP-1 receptor agonists have shown promising cardioprotective effects.
PCOS Ups Health and Hospitalization Risks
February 9, 2015
Women with polycystic ovary syndrome (PCOS) are at increased risk for metabolic and heart diseases and nearly twice as likely to be hospitalized.
